No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, March 24, 2011

No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting



of interest: "HE4 was not elevated in endometriosis"
CONCLUSIONS:
The major advantage of HE4 lies in its specificity and improved detection of borderline tumors and early stage ovarian and tubal cancers. HE4 is superior to CA125 with or without RMI and ROMA indices. However, we see no benefit from combining both markers in clinical practice.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.